Blood glutamate levels in major depression with antidepressants and benzodiazepines: A 6-month prospective cohort study.

IF 2.2 4区医学 Q3 PHARMACOLOGY & PHARMACY Therapie Pub Date : 2025-04-12 DOI:10.1016/j.therap.2025.04.003

Kahlil El Asmar, Tala El Ghoul, Romain Colle, Rida Assaf, Séverine Martin, Séverine Trabado, Bruno Feve, Céline Verstuyft, Laurent Becquemont, Emmanuelle Corruble

{"title":"Blood glutamate levels in major depression with antidepressants and benzodiazepines: A 6-month prospective cohort study.","authors":"Kahlil El Asmar, Tala El Ghoul, Romain Colle, Rida Assaf, Séverine Martin, Séverine Trabado, Bruno Feve, Céline Verstuyft, Laurent Becquemont, Emmanuelle Corruble","doi":"10.1016/j.therap.2025.04.003","DOIUrl":null,"url":null,"abstract":"Aim of the study: Our study aims at analyzing blood glutamate levels at three time points in patients on antidepressants and benzodiazepines across different subgroups.Methods: In the 6-month METADAP cohort study, blood glutamate levels were measured in 60 patients with major depression at baseline, 3 months (M3), and 6 months (M6) after starting antidepressant treatment. All patients received a co-prescription with benzodiazepines. Mixed-effect linear regression models were used to analyze the correlation of glutamate levels over time among responders, non-responders, remitters, and non-remitters, adjusting for multiple confounders.Results: Glutamate blood levels showed a significant decrease. Glutamate levels decreased from M0 to M3 across all subgroups. Responders and remitters showed a further decline from M3 to M6 while they increased non-significantly from M3 to M6 among non-responders and non-remitters. Responders showed a decrease of 3.38μmol/L [95% CI (-4.94; -1.82), P<0.001], while remitters showed a decrease of 1.34μmol/L [95% CI (-2.41; -0.27), P=0.014].Conclusion: Glutamate blood levels decreased from M0 to M3 across all groups but varied from M3 to M6: responders and remitters continued to decline, while non-responders and non-remitters showed a non-significant increase. These results should be replicated and further explained.","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.therap.2025.04.003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim of the study: Our study aims at analyzing blood glutamate levels at three time points in patients on antidepressants and benzodiazepines across different subgroups.

Methods: In the 6-month METADAP cohort study, blood glutamate levels were measured in 60 patients with major depression at baseline, 3 months (M3), and 6 months (M6) after starting antidepressant treatment. All patients received a co-prescription with benzodiazepines. Mixed-effect linear regression models were used to analyze the correlation of glutamate levels over time among responders, non-responders, remitters, and non-remitters, adjusting for multiple confounders.

Results: Glutamate blood levels showed a significant decrease. Glutamate levels decreased from M0 to M3 across all subgroups. Responders and remitters showed a further decline from M3 to M6 while they increased non-significantly from M3 to M6 among non-responders and non-remitters. Responders showed a decrease of 3.38μmol/L [95% CI (-4.94; -1.82), P<0.001], while remitters showed a decrease of 1.34μmol/L [95% CI (-2.41; -0.27), P=0.014].

Conclusion: Glutamate blood levels decreased from M0 to M3 across all groups but varied from M3 to M6: responders and remitters continued to decline, while non-responders and non-remitters showed a non-significant increase. These results should be replicated and further explained.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

服用抗抑郁药和苯二氮卓类药物的重度抑郁症患者血谷氨酸水平：一项为期6个月的前瞻性队列研究。

研究目的：我们的研究旨在分析不同亚组抗抑郁药和苯二氮卓类药物患者在三个时间点的血谷氨酸水平。方法：在为期6个月的METADAP队列研究中，在开始抗抑郁治疗后的基线、3个月（M3）和6个月（M6）测量60例重度抑郁症患者的血谷氨酸水平。所有患者都接受了苯二氮卓类药物的联合处方。混合效应线性回归模型用于分析反应者、无反应者、缓解者和非缓解者之间谷氨酸水平随时间的相关性，并对多个混杂因素进行调整。结果：血清谷氨酸水平明显降低。所有亚组的谷氨酸水平均从M0降至M3。反应者和缓解者从M3到M6进一步下降，而无反应者和非缓解者从M3到M6无显著增加。应答者降低了3.38μmol/L [95% CI (-4.94；结论：血清谷氨酸水平从M0到M3均有所下降，但从M3到M6有所不同：有反应者和缓解者持续下降，无反应者和非缓解者无显著升高。这些结果应该被复制并进一步解释。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapie 医学-药学

CiteScore

3.50

自引率

7.70%

发文量

132

审稿时长

57 days

期刊介绍： Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject. The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.

期刊最新文献

Retinal venous occlusion in drug-induced lupus. [The French IRB Study: Qualification of research by ethics committees]. Patients under treatment for sarcoidosis reported adherence issues and would welcome personalized pharmaceutical care: Results from survey online. Editorial board Contents